ENTITY
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (REGN US)

128
Analysis
Health CareUnited States
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
more
12 Nov 2016 07:59

Just In: Trump's Preliminary Plan to Repeal the Affordable Care Act

Among one of his first initiatives, U.S. President-elect Trump posted a preliminary plan to repeal the Affordable Care Act (ACA) on his transition...

11 Nov 2016 18:59

President Trump Taking America Back to the 1980s…

The Republican sweep in Washington and the unique nature of his insurgent victory means Trump faces fewer constraints on his power than any recent...

Logo
214 Views
Share
bullishCelgene Corp
11 Nov 2016 12:08

We Are Buying This Large Cap Biotechnology Company After Trump's Election Win

We have a Buy rating with price target of $173 (DCF method)=44% upside. The stock also appears to have upside using relative valuation measures...

11 Nov 2016 12:05

President Trump and Healthcare (And Pharma) Sector: What's Next?

Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare...

01 Nov 2016 13:06

Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update

 Acadia Pharmaceuticals Inc (ACAD US), our portfolio company announced the initiation of a phase 2 study of Nuplazid in Alzheimer's related...

x